Brandi E Stevens1, Kathryn S Torok2, Suzanne C Li3, Nicole Hershey2, Megan Curran4, Gloria C Higgins5, Katharine F Moore6, C Egla Rabinovich7, Samuel Dodson8, Anne M Stevens8. 1. Riley Hospital for Children at Indiana University Health, Indianapolis, and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. 2. University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. 3. Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, New Jersey. 4. Northwestern University Feinberg School of Medicine, Chicago, Illinois. 5. Ohio State University and Nationwide Children's Hospital, Columbus. 6. University of Colorado Children's Hospital Colorado, Aurora. 7. Duke University Medical Center, Durham, North Carolina. 8. University of Washington, Seattle.
Abstract
OBJECTIVE: To investigate clinical manifestations of juvenile systemic sclerosis (SSc; scleroderma), including disease characteristics and patient quality of life, using the multinational Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. METHODS: Patients with juvenile SSc were prospectively enrolled between 2010 and 2013. The diagnosis of juvenile SSc was determined by the enrolling pediatric rheumatologist, with the requirement for disease onset prior to age 18 years. Collected data included demographics, disease characteristics, medication exposure, and quality of life metrics. RESULTS: In total, 64 patients with juvenile SSc were enrolled a median of 3.6 years after disease onset, which occurred at a median age of 10.3 years. The most common organ manifestations were dermatologic and vascular, followed by musculoskeletal, gastrointestinal, and pulmonary; in 38% of patients, ≥4 organ systems were affected. Patients with juvenile SSc had significantly more disability at enrollment compared with CARRA Legacy Registry patients with juvenile idiopathic arthritis, dermatomyositis, or systemic lupus erythematosus. Although physician-reported measures correlated most closely with arthritis, dermatologic manifestations, and pulmonary manifestations, poor patient-reported measures were associated with gastrointestinal involvement. During >50 person-years of follow-up, most organ manifestations remained stable, and no mortality or development of new solid organ involvement after enrollment was reported. CONCLUSION: In the first multicenter prospective cohort of patients with juvenile SSc in North America, the disease burden was high: multiorgan manifestations were common, and functional disability was greater than that observed in patients with other childhood-onset rheumatic diseases. Gastrointestinal involvement had the greatest impact on quality of life.
OBJECTIVE: To investigate clinical manifestations of juvenile systemic sclerosis (SSc; scleroderma), including disease characteristics and patient quality of life, using the multinational Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. METHODS:Patients with juvenile SSc were prospectively enrolled between 2010 and 2013. The diagnosis of juvenile SSc was determined by the enrolling pediatric rheumatologist, with the requirement for disease onset prior to age 18 years. Collected data included demographics, disease characteristics, medication exposure, and quality of life metrics. RESULTS: In total, 64 patients with juvenile SSc were enrolled a median of 3.6 years after disease onset, which occurred at a median age of 10.3 years. The most common organ manifestations were dermatologic and vascular, followed by musculoskeletal, gastrointestinal, and pulmonary; in 38% of patients, ≥4 organ systems were affected. Patients with juvenile SSc had significantly more disability at enrollment compared with CARRA Legacy Registry patients with juvenile idiopathic arthritis, dermatomyositis, or systemic lupus erythematosus. Although physician-reported measures correlated most closely with arthritis, dermatologic manifestations, and pulmonary manifestations, poor patient-reported measures were associated with gastrointestinal involvement. During >50 person-years of follow-up, most organ manifestations remained stable, and no mortality or development of new solid organ involvement after enrollment was reported. CONCLUSION: In the first multicenter prospective cohort of patients with juvenile SSc in North America, the disease burden was high: multiorgan manifestations were common, and functional disability was greater than that observed in patients with other childhood-onset rheumatic diseases. Gastrointestinal involvement had the greatest impact on quality of life.
Authors: Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope Journal: Arthritis Rheum Date: 2013-10-03
Authors: N Ruperto; A Ravelli; A Pistorio; C Malattia; S Cavuto; L Gado-West; A Tortorelli; J M Landgraf; G Singh; A Martini Journal: Clin Exp Rheumatol Date: 2001 Jul-Aug Impact factor: 4.473
Authors: Giorgia Martini; Ivan Foeldvari; Ricardo Russo; Ruben Cuttica; Anne Eberhard; Angelo Ravelli; Thomas J A Lehman; Sheila Knupp Feitosa de Oliveira; Gordana Susic; Galina Lyskina; Dana Nemcova; Robert Sundel; Fernanda Falcini; Herman Girschick; Ana Paula Lotito; Antonella Buoncompagni; Flavio Sztajnbok; Sulaiman M Al-Mayouf; Ilonka Orbàn; Clodoveo Ferri; Balu H Athreya; Patricia Woo; Francesco Zulian Journal: Arthritis Rheum Date: 2006-12
Authors: Ariane L Herrick; Holly Ennis; Monica Bhushan; Alan J Silman; Eileen M Baildam Journal: Arthritis Care Res (Hoboken) Date: 2010-02 Impact factor: 4.794
Authors: Francesco Zulian; Patricia Woo; Balu H Athreya; Ronald M Laxer; Thomas A Medsger; Thomas J A Lehman; Marco Matucci Cerinic; Giorgia Martini; Angelo Ravelli; Ricardo Russo; Ruben Cuttica; Sheila Knupp Feitosa de Oliveira; Christopher P Denton; Franco Cozzi; Ivan Foeldvari; Nicolino Ruperto Journal: Arthritis Rheum Date: 2007-03-15
Authors: Kenneth Scalapino; Thaschawee Arkachaisri; Mary Lucas; Noreen Fertig; David J Helfrich; Aldo V Londino; Virginia D Steen; Thomas A Medsger Journal: J Rheumatol Date: 2006-04-01 Impact factor: 4.666
Authors: Angela Byun Robinson; Mark F Hoeltzel; Dawn M Wahezi; Mara L Becker; Elizabeth A Kessler; Heinrike Schmeling; Ruy Carrasco; Adam M Huber; Brian M Feldman; Ann M Reed Journal: Arthritis Care Res (Hoboken) Date: 2014-03 Impact factor: 4.794
Authors: Patrick Coit; Kaila L Schollaert; Emily M Mirizio; Kathryn S Torok; Amr H Sawalha Journal: Clin Immunol Date: 2021-05-13 Impact factor: 10.190
Authors: Anne M Stevens; Kathryn S Torok; Suzanne C Li; Sarah F Taber; Theresa T Lu; Francesco Zulian Journal: Front Immunol Date: 2019-06-25 Impact factor: 7.561